Researchers showed that LGP2 binds viral RNA ends and recruits MDA5 molecules to form filament clusters that activate ...
Discover how circular RNA technology enhances gene expression by up to 50-fold in eye treatments, surpassing traditional ...
A 45-nucleotide strand of RNA can now synthesize both its mirror-image complement and a copy of itself, bringing scientists ...
Two separate laboratory breakthroughs have produced RNA molecules that can build copies of themselves or assemble functional structures without any help from proteins or DNA. These results offer the ...
RNA therapeutics have been around since the late 1990s, but interest in these medicines has skyrocketed since the outbreak of the coronavirus pandemic and the success of messenger RNA (mRNA) vaccines.
Emerging modalities such as self-amplifying and circular RNA, expanding oncology and rare-disease applications, and scalable manufacturing are creating high-growth investment avenues, supported by ...
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced that it has obtained an exclusive, worldwide license to a novel and proprietary RNAi ...
SEONGNAM, South Korea, Aug. 3, 2023 /PRNewswire/ -- Rznomics developed a novel platform technology termed 'self-circularized RNA structure' that can efficiently and simply generate circular RNA and ...
Researchers have developed RNA therapeutics, called micelles, that can delivery chemotherapeutic drugs to metastasized tumors in mouse models.
Reduce amplification bias caused by variable miRNA abundance using automated PCR normalization for NEXTFLEX small RNA sequencing workflows.
Ottawa, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The global RNA therapeutics and vaccines market size is calculated at USD 0.38 billion in 2025 and is expected to reach around USD 107.7 billion by 2034, ...
CHICAGO, Sept. 15, 2023 /PRNewswire/ -- The RNA therapeutics industry is poised for a transformative surge in the near future. Breakthroughs in mRNA vaccine technology, exemplified by the rapid ...